|
Name |
Pullularin E
|
| Molecular Formula | C42H57N5O8 | |
| IUPAC Name* |
(6S,9S,12S,15S,18S)-3-benzyl-12-[(2S)-butan-2-yl]-6,7,13,15-tetramethyl-9-[[4-(3-methylbut-3-enoxy)phenyl]methyl]-4-oxa-1,7,10,13,16-pentazabicyclo[16.3.0]henicosane-2,5,8,11,14,17-hexone
|
|
| SMILES |
CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N([C@H](C(=O)OC(C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N1C)C)CC3=CC=CC=C3)C)C)CC4=CC=C(C=C4)OCCC(=C)C
|
|
| InChI |
InChI=1S/C42H57N5O8/c1-9-27(4)36-38(49)44-33(24-31-17-19-32(20-18-31)54-23-21-26(2)3)40(51)45(7)29(6)42(53)55-35(25-30-14-11-10-12-15-30)41(52)47-22-13-16-34(47)37(48)43-28(5)39(50)46(36)8/h10-12,14-15,17-20,27-29,33-36H,2,9,13,16,21-25H2,1,3-8H3,(H,43,48)(H,44,49)/t27-,28-,29-,33-,34-,35?,36-/m0/s1
|
|
| InChIKey |
SDUUWTNLMDCMFD-ZOPCHVBZSA-N
|
|
| Synonyms |
Pullularin E
|
|
| CAS | NA | |
| PubChem CID | 139586396 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 759.9 | ALogp: | 5.9 |
| HBD: | 2 | HBA: | 8 |
| Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 155.0 | Aromatic Rings: | 4 |
| Heavy Atoms: | 55 | QED Weighted: | 0.27 |
| Caco-2 Permeability: | -5.155 | MDCK Permeability: | 0.00004460 |
| Pgp-inhibitor: | 1 | Pgp-substrate: | 0.019 |
| Human Intestinal Absorption (HIA): | 0.055 | 20% Bioavailability (F20%): | 0.011 |
| 30% Bioavailability (F30%): | 0.851 |
| Blood-Brain-Barrier Penetration (BBB): | 0.008 | Plasma Protein Binding (PPB): | 85.27% |
| Volume Distribution (VD): | 0.531 | Fu: | 5.63% |
| CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.054 |
| CYP2C19-inhibitor: | 0.264 | CYP2C19-substrate: | 0.472 |
| CYP2C9-inhibitor: | 0.655 | CYP2C9-substrate: | 0.143 |
| CYP2D6-inhibitor: | 0.017 | CYP2D6-substrate: | 0.235 |
| CYP3A4-inhibitor: | 0.965 | CYP3A4-substrate: | 0.688 |
| Clearance (CL): | 7.204 | Half-life (T1/2): | 0.288 |
| hERG Blockers: | 0.052 | Human Hepatotoxicity (H-HT): | 0.991 |
| Drug-inuced Liver Injury (DILI): | 0.949 | AMES Toxicity: | 0.008 |
| Rat Oral Acute Toxicity: | 0.868 | Maximum Recommended Daily Dose: | 0.942 |
| Skin Sensitization: | 0.036 | Carcinogencity: | 0.025 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
| Respiratory Toxicity: | 0.025 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002484 | ![]() |
0.815 | D0E2OU | ![]() |
0.369 | ||
| ENC002483 | ![]() |
0.756 | D0J7XL | ![]() |
0.342 | ||
| ENC003591 | ![]() |
0.455 | D07XGH | ![]() |
0.305 | ||
| ENC003645 | ![]() |
0.429 | D05MNW | ![]() |
0.305 | ||
| ENC004971 | ![]() |
0.394 | D09PZZ | ![]() |
0.298 | ||
| ENC001481 | ![]() |
0.386 | D09NNH | ![]() |
0.298 | ||
| ENC002515 | ![]() |
0.373 | D0U7SH | ![]() |
0.295 | ||
| ENC003706 | ![]() |
0.369 | D01TSI | ![]() |
0.292 | ||
| ENC005563 | ![]() |
0.366 | D0N4OW | ![]() |
0.292 | ||
| ENC002514 | ![]() |
0.362 | D0D8XY | ![]() |
0.291 | ||